You searched for "cancer"

888 results found

The Royal Society of Medicine Partner Symposium: Genomics and prostate cancer – the latest in patient care

A joint meeting between Prostate Cancer UK, The Royal Marsden Hospital, the Institute of Cancer Research, and the Royal Society of Medicine.

The Royal Marsden: Gynaecological Cancers 2-Day Conference

Programme to reflect the breadth of professional expertise required to care for women with gynaecological cancers, and their diverse needs with an emphasis on practical skills. This study day is aimed at medical, nursing and allied health care professionals who are involved in the care of individuals with gynaecological cancer.

Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy

Neutrophil-to-lymphocyte ratio has been shown to be a prognostic factor in a number of different cancers. This is one of the largest studies to date to evaluate its effect on overall survival in patients who have undergone radical prostatectomy (RP)...

Dilemma of second primary tumour

Long-term survival in localised prostate cancer (CaP) can be achieved with treatment by either radical prostatectomy (RP) or external beam radiotherapy (EBRT). The development of second primary tumour is poorly understood in such cases. This retrospective study included 84,397 cases...

New senior appointments at The Urology Foundation

New Chief Executive appointed The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and...

The urologist’s tale

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). The Canterbury Tales, written by Geoffrey Chaucer (c.1340’s-1400) in the 14th Century, is...

New senior appointments at The Urology Foundation

The Urology Foundation (TUF) has appointed Rebecca Porta as Chief Executive. An established and experienced charity Chief Executive, Rebecca brings a wealth of experience having held senior roles within some of the UK’s leading health and medical research charities.

Multiparametric MRI with targeted-only biopsy – a new standard?

In this issue of European Urology, Kasivisvanathan et al. present a meta-analysis of two randomised trials comparing prebiopsy MRI with targeted biopsy (TBx) alone versus standard transrectal ultrasound-guided biopsy (TRUS-Bx) in biopsy-naïve men at risk of prostate cancer. Their findings...

Refining management of non-visible haematuria

The optimal evaluation of non-visible haematuria (NVH) continues to be debated, with competing interests of avoidance underdiagnosis and the harms of over-testing. Current National Institute for Health & Care Excellent (NICE) guidance recommends referral for patients ≥60 years with NVH....

PSA screening in limbo: how low should we go?

One may wonder how the management of prostate cancer could have evolved differently if it had followed a path similar to breast cancer. In breast cancer, early detection in the 1970s relied heavily on imaging because no reliable circulating biomarker...

BBS Revolution™ bladder scanner

Featuring a wireless scanning probe with eight ultrasound transducers for fully automatic bladder detection, BBS Revolution™ differentiates between male / female anatomy, delivering accurate volume measurements in seconds. Simple to use BBS Revolution™ is for...

Consensus statements on PSA testing in asymptomatic men in the UK

In January 2016, the UK National Screening Committee once again recommended against a systematic population screening programme for prostate cancer due to the, as yet, insufficient evidence that the benefits of screening would outweigh the harm to the population as...